Search Clinical Trials in the EU

Duration

6-10 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

221-240 of 604 trials

Long-Term Safety Study of Dabrafenib and Trametinib

We are evaluating the long-term safety of dabrafenib and trametinib for patients who have benefited from these treatments in previous studies. This study helps ensure continued access to these medications for those who need them.

Non-Small Cell Lung CancerMetastatic Melanoma1-2 yearsMonitoring phase (IV)6-10 visits Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Lung Transplant Rejection: Stem Cell Treatment Study

We are studying the safety of a new stem cell treatment for patients experiencing chronic rejection after a lung transplant. This trial aims to see if it can help slow down the progression of their condition.

Bronchiolitis Obliterans Syndrome (BOS)6-12 monthsEfficacy phase (II)6-10 visits No Placebo Investigational MedicinesInternal MedicinePulmonology

Crohn's Disease: Vedolizumab with Upadacitinib

We are studying whether a combination of vedolizumab and upadacitinib helps improve symptoms in adults with moderately to severely active Crohn's disease compared to vedolizumab alone.

Crohn's Disease>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyInternal Medicine

Cardiovascular Disease: Gene Analysis for Statin Treatment

We are studying whether a gene analysis strategy can help people at risk of cardiovascular disease better tolerate statins and reduce side effects. This trial compares this approach to standard treatment methods.

Patients at Risk of Cardiovascular Disease6-12 monthsMonitoring phase (IV)6-10 visits No Placebo Standard MedicinesCardiologyInternal Medicine

HIV-1 Treatment: Bictegravir/Lenacapavir for Kids and Teens

We are studying a new combination medication for children and adolescents with HIV-1 to see how well it works and how safe it is. The trial will also check if young patients find the medication easy to take.

HIV-1 Infection6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteInfectious DiseasesPediatrics

Advanced Solid Tumors: Datopotamab Deruxtecan Study

We are studying a new treatment for patients with advanced or metastatic solid tumors to see how well it works and its safety when used alone or with other cancer drugs.

Various Types of CancerEfficacy phase (II)6-10 visits No Placebo Investigational Medicines Partially RemoteOncology

HER2+ Cancer Treatment: Zongertinib Study

We are exploring the safety and effectiveness of zongertinib, alone and with other treatments, for patients with advanced HER2+ metastatic breast and gastric cancers. This study aims to find the best dose and understand how it may help manage these cancers.

Gastroesophageal Junction AdenocarcinomaEsophageal AdenocarcinomaMetastatic Breast CancerSafety phase (I)Efficacy phase (II)6-10 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteGastroenterologyOncology

Pleural Mesothelioma: Pembrolizumab with Chemotherapy

We are studying a combination of pembrolizumab and standard chemotherapy for patients with resectable epithelioid and biphasic pleural mesothelioma. The goal is to see if this treatment improves response rates and overall survival.

Malignant Pleural Mesothelioma1-2 yearsEfficacy phase (II)6-10 visits No Placebo Standard MedicinesOncology

Esophageal Cancer: Ifinatamab Deruxtecan Study

We are studying Ifinatamab Deruxtecan in patients with advanced esophageal squamous cell carcinoma who have already been treated. The goal is to see if it works better than standard chemotherapy options.

Esophageal Squamous Cell CarcinomaConfirmation phase (III)6-10 visits No Placebo Investigational Medicines Cost ReimbursementOncology

Ulcerative Colitis: Tofacitinib for Children

We are studying whether the oral medication tofacitinib can help children with moderately to severely active ulcerative colitis achieve remission. The trial will also look at how well the medication works and how it is accepted by young patients.

Ulcerative Colitis1-2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyPediatrics

Ponatinib for Pediatric Leukemias and Solid Tumors

We are studying the safety and effectiveness of ponatinib in children with recurrent or hard-to-treat leukemias and solid tumors. This trial aims to help those who have not responded to other therapies.

Acute Myeloid LeukaemiaChronic Myeloid Leukaemia1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematologyOncology

Fabry Disease: Venglustat Tablets

We are studying whether venglustat can improve heart health in adults with Fabry disease compared to standard treatments. The trial also looks at its effects on kidney function and overall well-being.

Fabry's Disease1-2 yearsConfirmation phase (III)6-10 visits No Placebo Investigational MedicinesCardiologyHematologyInternal Medicine

ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy Type 1

We are studying a new treatment for adults with Facioscapulohumeral Muscular Dystrophy Type 1 to see how safe it is and how it works in the body. This trial will help us understand its effects with different doses.

Facioscapulohumeral Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementInternal MedicineNeurology

Severe von Willebrand Disease: New Treatment Study

We are testing a new treatment for children with severe von Willebrand Disease to see if it helps control bleeding episodes and is safe during surgeries. The study will compare this treatment with and without an existing medication.

Von Willebrand's Factor Deficiency>2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementHematologyPediatrics

COVID-19 Treatment: Nirmatrelvir/Ritonavir for Children

We are studying a new oral medication for children with COVID-19 who are at risk of severe illness. The trial will evaluate its safety, how well it works, and how it is tolerated in young patients.

COVID-19Efficacy phase (II)Confirmation phase (III)6-10 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteInfectious DiseasesPediatrics

Pain Management in Heart Surgery: Interpectoral-Pectoserratus Block

We are studying a new pain relief technique for patients undergoing minimally invasive aortic valve replacement. The goal is to see if it improves pain control and recovery compared to a standard approach.

Aortic Valve Disease>2 yearsMonitoring phase (IV)6-10 visits Standard MedicinesCardiologyOtolaryngology

Childhood Leukemia: Inotuzumab Ozogamicin vs. ALLR3

We are studying whether Inotuzumab Ozogamicin works better than standard treatment for children with high-risk first relapse B-cell leukemia. The trial focuses on safety and long-term effectiveness in young patients.

Acute Lymphoblastic Leukemia6-12 monthsEfficacy phase (II)6-10 visits No Placebo Investigational Medicines Cost ReimbursementHematologyPediatrics

Acetyl-L-Carnitine for ALS Treatment

We are studying whether acetyl-L-carnitine can help slow down the progression of ALS and improve quality of life. Participants will receive different doses to see which is most effective and safe.

Amyotrophic Lateral Sclerosis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visits Investigational MedicinesNeurology

Liver Cirrhosis: Stopping Proton-Pump Inhibitors

We are studying whether stopping proton-pump inhibitors helps or harms patients with liver cirrhosis compared to those who continue the medication. This trial looks at hospitalizations, infections, and overall health outcomes.

Liver Cirrhosis1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visits Standard MedicinesGastroenterologyInternal Medicine

Severe von Willebrand Disease: Vonicog Alfa Prophylaxis

We are studying whether vonicog alfa can help prevent bleeding episodes in children with severe von Willebrand disease. The trial will also look at the safety of this treatment over time.

Von Willebrand Disease1-2 yearsConfirmation phase (III)6-10 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematology

Search Clinical Trials in the European Union